Children/adolescents with atopic dermatitis and a sleep disorder faced a greater risk for ADHD, anxiety, depression and ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Alkermes plc stands fourth on our list among the most ...

Hypersomnia causes excessive sleepiness, daytime sleep attacks, and difficulty waking. It can result from narcolepsy, sleep ...

Hypersomnia Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035 The report provides a detailed analysis of the current hypersomnia marketed drugs ...

Idiopathic Hypersomnia isn't just about fatigue-it's about reclaiming functionality. The evolving pipeline reflects a renewed commitment to waking lives trapped in excessive sleep.” ...

Explore the evolving competitive landscape in Idiopathic Hypersomnia Therapeutics with our comprehensive data-driven report. It covers epidemiology, market trends, pipeline insights, clinical trials, ...

Hypersomnia drug WASHINGTON — The Federal Circuit reversed a Delaware federal court’s decision to permanently enjoin Avadel CNS Pharmaceuticals from seeking FDA approval of its drug Lumryz, which is ...

Learn about the key differences between hypersomnia and narcolepsy, their symptoms, treatments, and how they affect daily life.

ALKS' phase II Vibrance-3 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with idiopathic hypersomnia.

Harmony said it expects to launch a Phase 3 registrational study of pitolisant HD in the fourth quarter, with a target of FDA approval in idiopathic hypersomnia in 2028.

A systematic review on diagnostic challenges and burden related to idiopathic hypersomnia gave insights into the extensive difficulties associated with the condition.